Essential Tremor - Pipeline Review, H2 2012

Global Markets Direct, October 2012, Pages: 37

Essential Tremor – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Essential Tremor - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Essential Tremor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Essential Tremor. Essential Tremor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Essential Tremor.
- A review of the Essential Tremor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Essential Tremor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Essential Tremor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Essential Tremor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Essential Tremor Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Essential Tremor 7
Essential Tremor Therapeutics under Development by Companies 9
Essential Tremor Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Essential Tremor Therapeutics – Products under Development by Companies 14
Essential Tremor Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Essential Tremor Therapeutics Development 16
Neurocrine Biosciences, Inc. 16
Manhattan Pharmaceuticals, Inc. 17
Sonexa Therapeutics, Inc. 18
Essential Tremor – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Antiepileptic Drugs - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
AST-915 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ST-101 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
octanoic acid - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
1-Octanol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
zonisamide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Essential Tremor Therapeutics – Drug Profile Updates 31
Essential Tremor Therapeutics - Dormant Products 33
Essential Tremor – Product Development Milestones 34
Featured News & Press Releases 34
Jan 04, 2012: Veloxis Initiates STRATO Study Of LCP-Tacro In Kidney Transplant Recipients Experiencing Tremors 34
Dec 16, 2010: Manhattan Pharmaceuticals Announces Preliminary Phase I/II Results For AST-915 In Essential Tremor 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Essential Tremor, H2 2012 7
Products under Development for Essential Tremor – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Neurocrine Biosciences, Inc., H2 2012 16
Manhattan Pharmaceuticals, Inc., H2 2012 17
Sonexa Therapeutics, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Essential Tremor Therapeutics – Drug Profile Updates 31
Essential Tremor Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Essential Tremor, H2 2012 7
Products under Development for Essential Tremor – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012